CD2 AND CD3 RECEPTOR-MEDIATED TOLERANCE
- 1 March 1999
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 67 (5) , 741-748
- https://doi.org/10.1097/00007890-199903150-00017
Abstract
Antigen specific allograft tolerance is induced in mice by anti-CD2 plus anti-CD3epsilon monoclonal antibody (mAb) treatment. Because anti-CD2 mAb inhibits several aspects of anti-CD3epsilon driven T cell activation, we investigated what components of T cell activation are required or may be dispensed with for tolerance induction. Anti-CD3epsilon-mediated T cell activation depends on FcgammaR interactions. To assess the role of FcgammaR-mediated T cell activation in tolerance induction, FcgammaR binding IgG or non-binding IgG3 anti-CD3epsilon mAbs were examined. These mAbs, administered in conjunction with anti-CD2, were equally effective in inducing tolerance. Moreover, in vivo administration of a blocking mAb directed against the FcgammaR, or the use of allograft recipients deficient in FcgammaR, had no effect on tolerance induction. Blocking IL-2 using mAb directed against IL-2 or IL-2R also did not prevent the induction of tolerance. These results suggest that complete T cell activation was not required for tolerance induction. However, substitution of a partially activating mAb, directed against the T cell receptor (TCR) beta subunit for anti-CD3epsilon, failed to synergize with anti-CD2 mAb to induce tolerance. The anti-TCRbeta mAb and anti-CD3epsilon mAb were found to differentially down modulate expression of TCR/CD3 complex subunits. In particular, anti-CD3epsilon caused transient down modulation of the TCRbeta receptor subunit and the TCRzeta signaling module, and this pattern was enhanced and prolonged by anti-CD2. Anti-TCRbeta caused persistent TCRzeta modulation but no TCRbeta modulation, and anti-CD2 did not influence this pattern. These results suggest that, although full T cell activation is not required for the induction of tolerance by anti-CD2 plus anti-CD3epsilon mAb, a signal transduction pathway that is associated with TCRbeta and TCRzeta expression, and, specifically, is perturbed by mAb binding of the CD3epsilon epitope, is critical.Keywords
This publication has 26 references indexed in Scilit:
- TCR Activation of ZAP70 Is Impaired in CD4+CD8+ Thymocytes as a Consequence of Intrathymic Interactions that Diminish Available p56lckImmunity, 1996
- COMPARISON OF IN VIVO EFFICACY AND MECHANISM OF ACTION OF ANTIMURINE MONOCLONAL ANTIBODIES DIRECTED AGAINST TCR αβ (H57–597) AND CD3 (145–2C11)Transplantation, 1995
- FcR γ chain deletion results in pleiotrophic effector cell defectsCell, 1994
- Combination Anti-CD2 and Anti-CD3 Monoclonal Antibodies Induce Tolerance While Altering lnterleukin-2, lnterleukin-4, Tumor Necrosis Factor, and Transforming Growth Factor-β ProductionAnnals of Surgery, 1993
- ANTI-CD2 AND ANTI-CD3 MONOCLONAL ANTIBODIES SYNERGIZE TO PROLONG ALLOGRAFT SURVIVAL WITH DECREASED SIDE EFFECTSTransplantation, 1993
- SPECIFIC UNRESPONSIVENESS IN RATS WITH PROLONGED CARDIAC ALLOGRAFT SURVIVAL AFTER TREATMENT WITH CYCLOSPORINETransplantation, 1993
- PROLONGATION OF ALLOGRAFT AND XENOGRAFT SURVIVAL IN MICE BY ANTI-CD2 MONOCLONAL ANTIBODIESTransplantation, 1992
- Antibody 12‐15 cross‐reacts with mouse Feγ receptors and CD2: study of thymus expression, genetic polymorphism and biosynthesis of the CD2 proteinEuropean Journal of Immunology, 1989
- Identification of a monoclonal antibody specific for a murine T3 polypeptide.Proceedings of the National Academy of Sciences, 1987
- Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.The Journal of Experimental Medicine, 1979